MARKETS
Markets

FDA Clears QIAGEN's Gram-Negative QIAstat-Dx Bloodstream Panel, Joining Gram-Positive And Fungal Panel To Cover 33 Pathogen Targets And 28 Resistance Marker

Sep 28, 2026 · 03:10 AM ET· updated 1h ago

Bloodstream infections can trigger sepsis, a life-threatening response to infection; about 1.7 million U.S. adults develop sepsis each year, contributing to at least 350,000 deathsNew QIAstat-Dx test identifies 13

Share
Why It Matters

QIAGEN got approval for a new blood test that finds dangerous infections faster. This shows the company is growing its tools that help doctors save lives.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.